The 3 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 18.00, with a high estimate of 26.00 and a low estimate of 10.00. The median estimate represents a +592.31% increase from the last price of 2.60.
The current consensus among 3 polled investment analysts is to Buy stock in BioLine RX Ltd. This rating has held steady since March, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.66
Reporting Date Mar 18
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.